( NASDAQ-NMS:ARQL )

News from daiichi sankyo company, limited and arqule, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 05, 2013, 09:00 ET Inclusion par Daiichi Sankyo et ArQule du premier patient atteint de carcinome hepatocellulaire (CHC) dans un essai international de phase 3 évaluant le tivantinib

Daiichi Sankyo Company, Limited (TSE 4568) et ArQule, Inc. (Nasdaq: ARQL) ont annoncé aujourd'hui que le premier patient avait été...


Jan 31, 2013, 13:03 ET Daiichi Sankyo y ArQule anuncian el reclutamiento del primer paciente enel estudio global fase III de tivantinib en carcinoma hepatocelular

- El estudio METIV-HCC analiza el papel de tivantinib, un inhibidor selectivo de MET, un receptor tirosina quinasa, en el tratamiento de...


Jan 31, 2013, 09:46 ET Daiichi Sankyo e Arqule annunciano l'arruolamento del 1° paziente con carcinoma epatocellulare nel trial clinico di fase 3 con tivantinib

Daiichi Sankyo (TSE 4568) e ArQule (Nasdaq: ARQL) hanno annunciato oggi l'arruolamento del primo paziente nello studio di  fase 3...